R 1479

Drug Profile

R 1479

Alternative Names: R-1479; RO 1048297

Latest Information Update: 27 Sep 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Argenta Discovery; Roche
  • Developer Roche
  • Class Antivirals; Nucleosides; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 27 Sep 2006 Discontinued - Phase-I for Hepatitis C treatment in United Kingdom (unspecified route)
  • 27 Sep 2006 Discontinued - Phase-I for Hepatitis C treatment in USA (unspecified route)
  • 27 Sep 2006 Discontinued as per oral presentation from Roche at the 232nd American Chemical Society National Meeting (232nd-ACS-2006,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top